NaF-PET/CT detects bone mets in prostate cancer patients

October 29, 2012

The use of PET/CT with a sodium fluoride (NaF) radiopharmaceutical produces high sensitivity, suggesting that the modality can be beneficial in detecting bone metastases caused by prostate cancer, according to a study published in the November issue of the American Journal of Roentgenology.

In a comparison with diffusion-weighted MRI (DWI-MRI), Swedish researchers found that NaF-PET/CT achieved greater sensitivity, while DWI-MRI achieved greater specificity in discovering bone metastases. The study's findings offer evidence that both modalities may be more efficient than bone scintigraphy, which traditionally has been the modality of choice to detect bone metastases in high-risk prostate cancer patients.